
|Videos|December 3, 2013
New Approaches to the Management of Metastatic Bladder Cancer
Author(s)Arjun Balar, MD
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses new approaches to the management of metastatic bladder cancer.
Advertisement
Clinical Pearls
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses new approaches to the management of metastatic bladder cancer.
- A phase III trial analyzing bevacizumab in combination with chemotherapy in metastatic bladder cancer is currently accruing
- OGX-427 is an antisense oligonucleotide against Hsp27, which is implicated in chemotherapy resistance
- It is hypothesized that OGX-427 added to chemotherapy could improve the sensitivity of a tumor to chemotherapy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5








































